|
tyyppi |
julkaisu |
3 |
Lehti |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
36 |
Lehti |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
58 |
Lehti |
Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161. |
73 |
Lehti |
Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |
81 |
Lehti |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
Lehti |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
93 |
Lehti |
Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
99 |
Lehti |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
103 |
Lehti |
Erickson SH, Ulici D. Incompatibility of cefotetan disodium and promethazine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 1347. |
106 |
Lehti |
Scott SM. Incompatibility of cefoperazone and promethazine. Am J Hosp Pharm 1990 ; 47: 519. |
124 |
Lehti |
Abubakar AA, Mustapha A, Wambebe OC. An in vitro interaction between promethazine hydrochloride and chloroquine phosphate. Int Pharm J 1993 ; 7: 14-19. |
169 |
Lehti |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
Lehti |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
249 |
Lehti |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
253 |
Lehti |
Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528. |
288 |
Lehti |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962. |
299 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
301 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
307 |
Lehti |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
334 |
Lehti |
Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992. |
335 |
Lehti |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
350 |
Lehti |
Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373. |
404 |
Lehti |
Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299. |
476 |
Lehti |
Knapp AJ, Mauro VF, Alexander KS. Incompatibility of ketorolac tromethamine with selected postoperative drugs. Am J Hosp Pharm 1992 ; 49: 2960-2962. |
492 |
Lehti |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
496 |
Lehti |
Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746. |
518 |
Lehti |
Jimenez MD. Visual compatibility of nalbuphine hydrochloride and promethazine hydrochloride. Am J Hosp Pharm 1988 ; 45: 1278. |
616 |
Lehti |
Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843. |
795 |
Lehti |
Henderson F. 21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette. Am J Health-Syst Pharm 1996 ; 53: 2338-2339. |
905 |
Lehti |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
921 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
1069 |
Lehti |
Peek BT, Webster KD, Da Camara CC. Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination. Am J Health-Syst Pharm 1999 ; 56: 1835-1838. |
1200 |
Lehti |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742. |
1228 |
Lehti |
Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381. |
1232 |
Lehti |
Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
1410 |
Lehti |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1415 |
Lehti |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1423 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1438 |
Lehti |
Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841. |
1496 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428. |
1625 |
Lehti |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1662 |
Lehti |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
1712 |
Lehti |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
1713 |
Lehti |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
1721 |
Lehti |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
1739 |
Lehti |
Scott SM. Incompatibility of cefperazone and promethazine. Am J Health-Syst Pharm 1990 ; 47: 519. |
1754 |
Lehti |
Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
1803 |
Lehti |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1925 |
Lehti |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1953 |
Lehti |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
2087 |
Lehti |
Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20. |
2109 |
Lehti |
Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75. |
2179 |
Lehti |
Trusley C, Ben M, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound 2007 ; 11, 1: 82-85. |
2269 |
Lehti |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
3012 |
Lehti |
Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
3216 |
Lehti |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
3249 |
Lehti |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3408 |
Lehti |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3531 |
Laboratorio |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014 |
3539 |
Laboratorio |
Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013 |
3540 |
Laboratorio |
Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 |
3585 |
Laboratorio |
Benzylpenicillin sodium - Summary of Product Characteristics Genus Pharmaceuticals 2008 |
3593 |
Laboratorio |
Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics Beacon Pharmaceuticals 2011 |
3599 |
Laboratorio |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013 |
3637 |
Laboratorio |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014 |
3672 |
Laboratorio |
Nalbuphine Mylan - Résumé des caractéristiques du produit Mylan SAS 2016 |
3674 |
Laboratorio |
Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
3675 |
Laboratorio |
Thiopental sodium - Summary of Product Characteristics Archimedes Pharma UK Ltd 2015 |
3767 |
Lehti |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |
3964 |
Lehti |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
4650 |
Laboratorio |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |